enGene Therapeutics
ENGN
31 hedge funds and large institutions have $536M invested in enGene Therapeutics in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 2
309% more capital invested
Capital invested by funds: $131M → $536M (+$405M)
182% more funds holding
Funds holding: 11 → 31 (+20)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
11.49% more ownership
Funds ownership: 61.15% → 72.64% (+11%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$31.4M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$27.5M |
| 3 |
CC
Commodore Capital
New York
|
+$15.3M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
+$15M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$671K |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$633K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$366K |
| 4 |
Goldman Sachs
New York
|
-$346K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.9K |
ENGN Hedge Fund Activity: Q1 2024 in Review
31 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q1 2024, worth a combined $536M — up 309% from $131M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ENGN positions and 2 closed out — a net gain of 20 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $31.4M. The largest seller was Omega Fund Management, cutting an estimated $671K.
- 31 institutional investors held enGene Therapeutics (ENGN) as of Q1 2024, up from 11 in Q4 2023.
- Funds reported $536M of enGene Therapeutics stock for Q1 2024, up 309% quarter-over-quarter.
- 22 funds opened new enGene Therapeutics positions in Q1 2024 and 2 closed out, a net change of +20 holders.
- The largest enGene Therapeutics buyer in Q1 2024 was VR Adviser, an estimated $31.4M added.
- The largest enGene Therapeutics seller in Q1 2024 was Omega Fund Management, an estimated $671K sold.
Based on aggregated 13F filings for Q1 2024.